EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics

Paolo Gisondi, Francesco Bellinato, Carlotta Galeone, Federica Turati, Luca Idolazzi, Alen Zabotti, Dennis McGonagle, Giampiero Girolomoni

Annals of the Rheumatic Diseases · 2025-03 · 84 (3) · 435-441

DOI: 10.1016/j.ard.2025.01.006 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-03. Verfasst von Paolo Gisondi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology and Venereology, University of Verona, Verona, Italy. Electronic address: paolo.gisondi@univr.it. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Biological Products, Psoriasis, Antirheumatic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: NIHR Leeds Musculoskeletal Biomedical Research Unit, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To investigate the risk of psoriatic arthritis (PsA) in plaque psoriasis (PsO) patients receiving different classes of biologics. METHODS: A retrospective observational study involving consecutive bionaïve PsO patients starting biologic treatment was performed. We compared the occurrence of PsA by the class of the biologic (tumour necrosis factor [TNF], interleukin [IL]-17, or IL-23 inhibitors) using inverse probability of treatment weighting (IPTW) in the setting of multiple treatments to balance pretreatment covariates across cohorts and thus adjust for potential confounders. An IPTW Cox regression model was used to estimate hazard ratios (HRs) of PsA for IL-17 and IL-23 inhibitors versus TNF inhibitors. RESULTS: In total, 622 patients, 430 (62.4%) males, mean ± SD age 46.9 ± 12.9 years, were included. They have been treated with TNF (n = 317, 50.9%), IL-17 (n = 164, 26.4%) or IL-23 inhibitors (n = 141, 22.7%) and followed for 2510 person-years (a mean of 4.1 ± 2.1 years per person). TNF, IL-17, and IL-23 inhibitor cohorts had a total of 1569, 486, and 455 person-years of follow-up. A total of 60 (10%) out of 622 patients on biologic therapy developed incident PsA during the observation period: 45 (14.2%) in the TNF, 9 (5.5%) in the IL-17, and 6 (4.3%) in the IL-23 inhibitor cohorts. After IPTW, the 3 treatment cohorts were well-balanced, and the HRs of PsA were 0.63 (95% CI, 0.38-1.05) for IL-17 and 0.57 (95% CI, 0.34-0.96) for IL-23 compared with the TNF treatment group. CONCLUSIONS: The risk of developing PsA appeared slightly different in patients receiving diverse classes of biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticBiological ProductsPsoriasisAntirheumatic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultInterleukin-23Interleukin-17Tumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Substanzen

Biological ProductsInterleukin-23Interleukin-17Tumor Necrosis Factor-alphaAntirheumatic AgentsTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Section of Dermatology and Venereology, University of Verona, Verona, Italy. Electronic address: paolo.gisondi@univr.it.
  • Section of Dermatology and Venereology, University of Verona, Verona, Italy.
  • Bicocca Applied Statistics Center (B-ASC), Università degli Studi di Milano-Bicocca, Milan, Italy.
  • Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy.
  • Section of Rheumatology, University of Verona, Verona, Italy.
  • Department of Medical and Biological Sciences, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; LTHT, NIHR Leeds Biomedical Research Centre, Leeds, UK.

Förderung

  • NIHR Leeds Musculoskeletal Biomedical Research Unit
  • European Union

Zitieren

APA

Gisondi, P., Bellinato, F., Galeone, C., Turati, F., Idolazzi, L., Zabotti, A., McGonagle, D., & Girolomoni, G. (2025). Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics. Annals of the Rheumatic Diseases, 84(3), 435-441. https://doi.org/10.1016/j.ard.2025.01.006

Vancouver

Gisondi P, Bellinato F, Galeone C, Turati F, Idolazzi L, Zabotti A, et al. Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics. Annals of the Rheumatic Diseases. 2025;84(3):435-441. doi:10.1016/j.ard.2025.01.006

BibTeX
@article{Gisondi2025,
  author = {Gisondi, Paolo and Bellinato, Francesco and Galeone, Carlotta and Turati, Federica and Idolazzi, Luca and Zabotti, Alen and McGonagle, Dennis and Girolomoni, Giampiero},
  title = {Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {3},
  pages = {435--441},
  doi = {10.1016/j.ard.2025.01.006}
}
Kostenlos starten →